Pharma Mar, S.A. (PHMMF)

Market Cap	1.79B
Revenue (ttm)	222.27M
Net Income (ttm)	49.34M
Shares Out	n/a
EPS (ttm)	n/a
PE Ratio	36.29
Forward PE	21.91
Dividend	n/a
Ex-Dividend Date	n/a

Volume	300
Average Volume	18
Open	91.45
Previous Close	99.90
Day's Range	91.22 - 99.90
52-Week Range	45.85 - 105.60
Beta	-0.09
RSI	87.91
Earnings Date	Oct 28, 2025

About Pharma Mar

Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata for the treatment of soft tissue sarcoma and recurrent ovarian cancer; Aplidin i...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 500
• Stock Exchange: OTCMKTS
• Ticker Symbol: PHMMF

Financial Performance

In 2024, Pharma Mar's revenue was 174.86 million, an increase of 10.56% compared to the previous year's 158.15 million. Earnings were 26.13 million, an increase of 2197.71%.

Financial numbers in EUR